Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
The phase III study included patients who received at least one prior line of therapy.
The researchers sought to assess the utility of MRD outside the context of clinical trials.
Daratumumab in combination with lenalidomide and dexamethasone provided greater OS in most subgroups.
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
Advertisement
Researchers examined tumor-intrinsic factors that promote multiple myeloma antigen escape.
Ajay Nooka, MD, FACP, discusses the data behind the FDA accelerated approval of elranatamab.
Dr. Nooka, who served as an investigator on the MagnetisMM-3 trial, discusses the impact of the accelerated approval.
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
The bispecific antibody received Breakthrough Therapy Designation from the FDA in November 2022.
There was no significant difference in the number of mutations present at diagnosis between the two groups of patients.
The researchers used a cumulative deficit approach to calculate a frailty index score at diagnosis and at landmark intervals.
It is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase.
More than one-quarter of the patients required a dose reduction due to adverse events.
The US FDA and NMPA have approved IND applications for LBL-034 for the treatment of relapsed or refractory multiple myeloma.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
Dr. Cerchione discusses the importance of ensuring adequate representation in multiple myeloma clinical trials.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.